相关实验视频

Updated: Sep 16, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

评估氨酸激酶抑制剂对EGFR突变的有效性

Hanshuang Shao¹, Alan Wells^1,2

¹Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA.

International journal of molecular sciences

|July 12, 2025

概括

EGFR突变驱动癌症,但抗药性发展. 这项研究对EGFR抑制剂对常见突变进行了测试,揭示了不同TKI代的表现,并为个性化癌症治疗策略提供了信息.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

皮表皮生长因子受体 (EGFR) 突变是许多固体瘤的关键驱动因素,导致针对性治疗,如氨酸激酶抑制剂 (TKI).
瘤对TKIs的耐药性通常是由二次EGFR突变引起的,这使治疗疗效复杂化.
常见的EGFR突变 (L858R,T790M,C797S) 和它们的组合对现有的非小细胞肺癌的TKI提出了挑战.

研究的目的:

评估不同代EGFRTKI对各种EGFR突变及其组合的体外疗效.
阐明特定EGFR突变变异型对临床TKIs的响应模式.
为优化TKI治疗策略和了解TKI耐药机制提供见解.

主要方法:

一系列EGFR突变的构建和体外评估.
测试第一代 (erlotinib),第三代 (osimertinib) 和第四代 (EAI045) TKI 对EGFR自酸化的抑制作用.
在不同细胞介质条件下评估TKI疗效 (完全生长与静止).

主要成果:

埃洛提尼布对含有T790M突变的疗效有限.
奥西默提尼布有效抑制了野生型和几种常见突变,但对T790M/C797S变种无效.
EAI045在大多数突变中表现出广泛的疗效,在特定条件下有部分抑制,并建议自化在T790M/L858R和T790M/C797S/L858R耐药性中发挥作用.

结论:

不同的TKI代表现出针对特定EGFR突变的独特活动概况.
了解TKI对EGFR变异的反应对于个性化非小细胞肺癌治疗至关重要.
该研究突出了TKI耐药性的潜在机制,并为开发更有效的向治疗提供了信息.

关键词:

欧洲农业基金会 (EGFR) 是一个基金.这就是TKI.酸化的方法是:光化.电阻的电阻是指电阻的电阻

更多相关视频

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...